Protagonist Therapeutics, Inc. (PTGX)
NASDAQ: PTGX · Real-Time Price · USD
98.97
+0.45 (0.46%)
At close: Apr 30, 2026, 4:00 PM EDT
99.50
+0.53 (0.54%)
After-hours: Apr 30, 2026, 5:39 PM EDT
Protagonist Therapeutics Stock Forecast
Stock Price Forecast
The 13 analysts that cover Protagonist Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $108.23, which forecasts a 9.36% increase in the stock price over the next year. The lowest target is $82 and the highest is $125.
Price Target: $108.23 (+9.36%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Protagonist Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 6 | 6 | 7 |
| Buy | 5 | 5 | 5 | 5 | 5 | 5 |
| Hold | 0 | 0 | 0 | 0 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 9 | 11 | 12 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Truist Securities | Truist Securities | Strong Buy Maintains $110 → $121 | Strong Buy | Maintains | $110 → $121 | +22.26% | Apr 15, 2026 |
| Clear Street | Clear Street | Strong Buy Maintains $104 → $116 | Strong Buy | Maintains | $104 → $116 | +17.21% | Apr 7, 2026 |
| Leerink Partners | Leerink Partners | Buy Maintains $107 → $110 | Buy | Maintains | $107 → $110 | +11.14% | Mar 19, 2026 |
| JP Morgan | JP Morgan | Buy Maintains $95 → $106 | Buy | Maintains | $95 → $106 | +7.10% | Mar 19, 2026 |
| Citigroup | Citigroup | Strong Buy Maintains $115 → $125 | Strong Buy | Maintains | $115 → $125 | +26.30% | Mar 19, 2026 |
Financial Forecast
Revenue This Year
448.31M
from 46.02M
Increased by 874.25%
Revenue Next Year
149.64M
from 448.31M
Decreased by -66.62%
EPS This Year
3.33
from -2.05
EPS Next Year
-0.69
from 3.33
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 641.6M | 461.0M | ||||||
| Avg | 448.3M | 149.6M | ||||||
| Low | 22.8M | 40.2M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 1,294.2% | 2.8% | ||||||
| Avg | 874.2% | -66.6% | ||||||
| Low | -50.5% | -91.0% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 6.97 | 3.53 | ||||||
| Avg | 3.33 | -0.69 | ||||||
| Low | -2.90 | -2.59 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | 6.1% | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.